ALFA Finder| Revenue growth | FY26 up 14% YoY; Q4FY26 up 19% YoY. |
|---|---|
| Margins | H1FY27 margins temporarily impacted; H2FY27 recovery to 17-18%. |
| Demand visibility | Strong growth in Ruby-Fill; biotech demand expected to improve. |
| Management confidence | High confidence in regulatory path for MIBG and pipeline acceleration. |
Growth
FY26 Revenue up 14% to ₹8,280 Cr; EBITDA up 8% to ₹1,326 Cr; Normalized PAT up 7% to ₹4,422 Cr.
Outlook
Guided H2FY27 EBITDA margins of 17-18%. Committed to net debt zero by 2030. Commencing commercial production on Line 3 late FY2027.
Risks
Short-term margin pressure in H1FY27 due to SPECT product supply shortages and lower production at CMO Montreal.
Earnings Call filed with BSE, NSE: JUBLPHARMA. Summary written with AI assistance from the document.
Jubilant Pharmova Ltd: key numbers
- Share price
- ₹992.85
- Market cap
- ₹15,814 Cr
- Revenue (annual)
- ₹8,280 Cr
- Net profit (annual)
- ₹398.5 Cr
- P/E (TTM)
- 44.9×Sector 43.8×
- Promoter holding
- 47.68%+0.00% QoQ
- FII holding
- 15.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jubilant Pharmova Ltd
All →Jubilant Pharmova Business Update
Jubilant Pharmova's subsidiary Jubilant Therapeutics will present preliminary Phase 1 clinical data for JBI-802 at the 68th ASH meeting. A company event on December 14, 2026 will discuss the data.
Jubilant Pharmova Debt & Borrowing: ₹800 Cr
Jubilant Pharmova allotted 80,000 unsecured NCDs worth Rs 800 Crore on a private placement basis. The 8.50% debentures mature in November 2028.
- Value
- ₹800.0 Cr
- Execution
- 3 years (maturity 05 November 2028)
Jubilant Pharmova Board Meeting Date
Jubilant Pharmova has scheduled a board meeting for November 13, 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. The filing is a Regulation 29 advance intimation only.
Jubilant Pharmova Annual General Meeting
Jubilant Pharmova Ltd has issued a Postal Ballot Notice seeking shareholder approval for the private placement issuance of Non-Convertible Debentures.
Jubilant Pharmova Credit Rating
Jubilant Pharmova received a credit rating of IND AA+/Stable from India Ratings and Research for its proposed Non-Convertible Debentures worth ₹1,400 Crore.
- Value
- ₹1,400 Cr
Jubilant Pharmova Other Announcement
Jubilant Pharmova Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.